X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs SANOFI INDIA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER SANOFI INDIA PFIZER/
SANOFI INDIA
 
P/E (TTM) x 36.4 39.9 91.3% View Chart
P/BV x 5.4 8.6 62.3% View Chart
Dividend Yield % 0.6 1.0 60.7%  

Financials

 PFIZER   SANOFI INDIA
EQUITY SHARE DATA
    PFIZER
Mar-18
SANOFI INDIA
Dec-16
PFIZER/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs2,3654,560 51.9%   
Low Rs1,6254,400 36.9%   
Sales per share (Unadj.) Rs430.31,028.5 41.8%  
Earnings per share (Unadj.) Rs78.7129.0 61.0%  
Cash flow per share (Unadj.) Rs93.2186.0 50.1%  
Dividends per share (Unadj.) Rs20.0068.00 29.4%  
Dividend yield (eoy) %1.01.5 66.0%  
Book value per share (Unadj.) Rs586.5753.6 77.8%  
Shares outstanding (eoy) m45.7523.03 198.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.64.4 106.4%   
Avg P/E ratio x25.334.7 73.0%  
P/CF ratio (eoy) x21.424.1 88.9%  
Price / Book Value ratio x3.45.9 57.2%  
Dividend payout %25.452.7 48.2%   
Avg Mkt Cap Rs m91,271103,174 88.5%   
No. of employees `0002.63.6 72.6%   
Total wages/salary Rs m3,1433,592 87.5%   
Avg. sales/employee Rs Th7,484.86,537.7 114.5%   
Avg. wages/employee Rs Th1,195.0991.4 120.5%   
Avg. net profit/employee Rs Th1,369.1819.8 167.0%   
INCOME DATA
Net Sales Rs m19,68523,686 83.1%  
Other income Rs m1,143708 161.4%   
Total revenues Rs m20,82824,394 85.4%   
Gross profit Rs m5,0035,281 94.7%  
Depreciation Rs m6631,313 50.5%   
Interest Rs m415 28.0%   
Profit before tax Rs m5,4794,661 117.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8781,691 111.1%   
Profit after tax Rs m3,6012,970 121.2%  
Gross profit margin %25.422.3 114.0%  
Effective tax rate %34.336.3 94.5%   
Net profit margin %18.312.5 145.9%  
BALANCE SHEET DATA
Current assets Rs m24,16715,673 154.2%   
Current liabilities Rs m9,5446,678 142.9%   
Net working cap to sales %74.338.0 195.6%  
Current ratio x2.52.3 107.9%  
Inventory Days Days5576 72.5%  
Debtors Days Days2922 128.6%  
Net fixed assets Rs m9,5148,098 117.5%   
Share capital Rs m458230 198.7%   
"Free" reserves Rs m26,37517,088 154.3%   
Net worth Rs m26,83217,356 154.6%   
Long term debt Rs m250-   
Total assets Rs m36,90025,400 145.3%  
Interest coverage x1,305.5311.7 418.8%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.9 57.2%   
Return on assets %9.811.8 83.1%  
Return on equity %13.417.1 78.4%  
Return on capital %20.426.9 75.8%  
Exports to sales %024.5 0.0%   
Imports to sales %028.0 0.0%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs mNA6,627 0.0%   
Fx inflow Rs m227,145 0.3%   
Fx outflow Rs m1,4896,846 21.7%   
Net fx Rs m-1,466299 -490.4%   
CASH FLOW
From Operations Rs m3,3183,226 102.9%  
From Investments Rs m-2,383-1,555 153.2%  
From Financial Activity Rs m-1,104-1,818 60.7%  
Net Cashflow Rs m-169-147 114.6%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 63.9 60.4 105.8%  
Indian inst/Mut Fund % 7.5 14.4 52.1%  
FIIs % 4.9 14.6 33.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 10.5 225.7%  
Shareholders   85,207 15,184 561.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   ALEMBIC LTD  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare PFIZER With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Sep 21, 2018 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS